Redeye Healthcare Day 2026
9 April, 2026
We are excited to announce our participation in the upcoming Redeye Healthcare Day 2026 on 14 April 2026. Join us for live presentations on this link. Nanologica will present at 16.45.
ABOUT NANOLOGICA
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues.
Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The Group also includes Syntagon, a contract manufacturer of drug molecules for both clinical studies and commercial delivery. Syntagon works with chemical engineering manufacturing and the development of processes and analyses of pharmaceutical raw materials, with a core competence in small molecules and peptides, and a particular strength in purification and analysis of complex compounds.
Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
OM NANOLOGICA
Vd Andreas Bhagwani berättar om Nanologica och den pågående företrädesemissionen.
NLAB Saga®
A NEW GENERATION SILICA FOR PREPARATIVE CHROMATOGRAPHY
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
For more information and order information, please see our catalogue below or contact us!
Latest News
Number of Shares and Votes in Nanologica AB (publ)
31 March, 2026
The number of registered shares and votes in Nanologica AB has changed during the month of March as a result of the directed share issues resolved by the board of directors on 30 January 2026 and approved at the subsequent extraordinary general meeting on 4 March 2026 (the “Directed Issues”). The Directed Issues comprised a
Event at Nanologica’s Premises – No Damage to Personnel or Instruments
29 March, 2026
Over the weekend, a minor explosion occurred in an oven at a company that shares an office and laboratory corridor with Nanologica. The sprinkler system was activated automatically, and water was spread throughout the premises. No one has been injured and Nanologica’s equipment is unharmed. The initial assessment shows that none of Nanologica’s instruments or
Listen to our team talk about Nlab Saga®
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.